| Unique ID issued by UMIN | UMIN000056217 |
|---|---|
| Receipt number | R000064230 |
| Scientific Title | A verification study to evaluate the safety of long-term consumption of the test food: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
| Date of disclosure of the study information | 2024/11/20 |
| Last modified on | 2025/08/28 11:25:15 |
A verification study to evaluate the safety of long-term consumption of the test food
A verification study to evaluate the safety of long-term consumption of the test food
A verification study to evaluate the safety of long-term consumption of the test food: a randomized, placebo-controlled, double-blind, parallel-group comparison study
A verification study to evaluate the safety of long-term consumption of the test food
| Japan |
Healthy Japanese
| Not applicable | Adult |
Others
NO
To verify the safety of consumption of plasmalogen-containing food for 12 weeks in healthy Japanese. Additionally, to exploratorily measure blood plasmalogen levels and verify the effects of plasmalogen-containing food on sleep during the intervention period.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1. Individuals who experienced adverse events
1. Individuals whose values of blood test and urinalysis are outside the reference range after intervention despite within the reference range at screening (before intervention; Scr)
<Exploratory outcomes>
1. The measured values of blood plasmalogen levels at 6 and 12 weeks after intervention (6w and 12w), and changes of them from Scr
2. Items in the St. Mary's Hospital Sleep Questionnaire (SMH) at 6w and 12w
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
Institution is not considered as adjustment factor.
YES
2
Educational,Counseling,Training
| Food |
Duration: 12 weeks
Test food: Food containing plasmalogen
Administration: Take five capsules per day in the morning.
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
Duration: 12 weeks
Test food: Food not containing plasmalogen
Administration: Take five capsules per day in the morning.
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
Individuals who
1. are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. are undergoing medical treatment or have a medical history for any of the following diseases: mental disorder (such as depression), sleep apnea syndrome, hypersomnia, narcolepsy, insomnia, or valvular heart disease
5. have habits of consuming foods or using devices to improve sleep
6. have irregular sleeping habits due to lifestyle such as night shifts
7. fall under the following sleeping conditions: sleeping in the same room with two or more people, living with preschool-aged children, living with individuals who require nursing care, or having their sleep potentially disturbed by the influence of others
8. have nocturia two times or more
9. usually drink to excess (average of more than about 20 g/day as absolute alcohol intake) {500 mL: a medium bottle of beer or about 1.5 cans of canned chu-hi, 180 mL: 1 go of sake or about 1.5 glasses of wine, 90 mL: half-go with shochu, 60 mL: a glass of whiskey brandy (double)}
10. are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
11. are taking medications (including herbal medicines) or supplements
12. are allergic to medicines or foods related to the test product
13. are pregnant, lactating, or planning to become pregnant during this study
14. have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
15. are judged as ineligible to participate in this study by the physician
20
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
03-3818-0610
nao@orthomedico.jp
ORTHOMEDICO Inc.
AOBA KASEI CO., LTD.
Profit organization
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
YES
NCT06715475
ClinicalTrials.gov
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
| 2024 | Year | 11 | Month | 20 | Day |
Unpublished
24
Completed
| 2024 | Year | 11 | Month | 13 | Day |
| 2024 | Year | 11 | Month | 13 | Day |
| 2024 | Year | 11 | Month | 20 | Day |
| 2025 | Year | 04 | Month | 23 | Day |
| 2024 | Year | 11 | Month | 20 | Day |
| 2025 | Year | 08 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064230